News
The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...
2d
Bizcommunity.com on MSNAfrican start-ups take on medicine access gaps with smarter supply chainsA healthcare-focused panel discussion at this year’s Sapics Conference in Cape Town spotlighted Africa’s emergence as a ...
21d
Zacks Investment Research on MSNWill Cencora (COR) Beat Estimates Again in Its Next Earnings Report?Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Cencora (COR), which belongs to the Zacks ...
But as she explained, African-led innovators are working to close these gaps through technology, data and new business models ...
In the third part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of supply chain operations & ...
In the first part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of supply chain operations & ...
In April 2025, the retailer introduced the PharmStart initiative, a program that covers the full cost of online prerequisite ...
GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.
Steve Collis’ three decades of experience at a major drug distributor could prove helpful for Elevance as it continues to ...
Florida’s importation program hasn’t brought in a single Canadian drug. It’s not cost-effective and it could be dangerous.
We came across a bullish thesis on Cencora, Inc. on Stock Analysis Compilation’s Substack. In this article, we will summarize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results